824 related articles for article (PubMed ID: 23532369)
1. IDH1 and IDH2 mutations in gliomas.
Cohen AL; Holmen SL; Colman H
Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
[TBL] [Abstract][Full Text] [Related]
2. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
4. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K
Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
[TBL] [Abstract][Full Text] [Related]
7. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
10. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
13. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
16. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
17. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
19. Consequences of
Kaminska B; Czapski B; Guzik R; Król SK; Gielniewski B
Molecules; 2019 Mar; 24(5):. PubMed ID: 30857299
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
Schaap FG; French PJ; Bovée JV
Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]